New partnership between BetterYou and University of Sheffield paves way for vitamin D research

A new collaboration between health pioneers BetterYou and scientists from the University of Sheffield, is paving the way for a three-year clinical trial looking at the effect of vitamin D supplementation on the quality of life of people with Irritable Bowel Syndrome (IBS).

The three-phase PhD will begin in October in partnership with Dr Bernard Corfe and Dr Liz Williams from the University’s Department of Oncology and Metabolism. The trial is designed to look at:

• The uptake rate of vitamin D delivery – BetterYou DLux3000 spray versus 3000IU tablet
• A randomised control trial looking at how supplementing with vitamin D effects quality of life in IBS sufferers
• A population study comparing vitamin D intakes of IBS sufferers compared to national data.

The new study builds on existing findings by Dr Bernard Corfe, linking vitamin D deficiency to IBS and suggesting that the sunshine vitamin could further impact on quality of life of people with IBS.

Dr Bernard Corfe said:

IBS can have a very significant impact on the life of people diagnosed with it. The potential link between vitamin D intake and IBS symptoms is a new one and we are delighted to be working with BetterYou to investigate the potential to improve the lives and health of people with IBS.

Andrew Thomas, founder and managing director of BetterYou, said:

We are proud to work with a world-leading university held in such high regard for its research excellence.

We take pride in our continued absorption research within the field of oral spray delivery. There are few supplement products on the market more stringently researched and tested.

The start of this trial comes at an exciting time for us, as we continue to support the annual Vitamin D Awareness Week campaign (24-30 October 2016). Deficiency is linked with a number of conditions and we hope that by raising awareness we can help improve the quality of people’s lives and eradicate vitamin D deficiency in the UK by 2020.

Findings from each phase of the trial will be reported on each year.